Jessica Leung1, James J Sejvar2, Jesus Soares2, Tatiana M Lanzieri3. 1. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, MS H24-5, Atlanta, GA, 30333, USA. JLeung@cdc.gov. 2. Division of High-Consequence Pathogens and Pathology, Prion and Public Health Office, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. 3. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, MS H24-5, Atlanta, GA, 30333, USA.
Abstract
OBJECTIVE: To describe incidence and clinical characteristics of cases of Guillain-Barré syndrome (GBS) in the USA during 2009-2015, and characteristics of GBS cases with antecedent cytomegalovirus (CMV) infection among persons with employer-sponsored insurance. METHODS: We analyzed medical claims from IBM Watson MarketScan® databases. GBS patients were defined as enrollees with an inpatient claim with GBS as the principal diagnosis code, based on ICD-9 or ICD-10, and ≥ 1 claim for lumbar puncture or EMG/nerve conduction study. We assessed intensive care unit (ICU) hospitalization, intubation, dysautonomia, and death. We also assessed selected infectious illness within 60 days prior to the first GBS-coded inpatient claim. RESULTS: We identified 3486 GBS patients; annual incidence was 1.0-1.2/100,000 persons during 2009-2015. GBS incidence was higher in males (1.2/100,000) than in females (0.9/100,000) (p = 0.006) and increased with age, from 0.4/100,000 in persons 0-17 years old to 2.1/100,000 in persons ≥ 65 years old (p < 0.001). Half of GBS patients were hospitalized in the ICU, 8% were intubated, 2% developed dysautonomia, and 1% died. Half had a claim for antecedent illness, but only 125 (3.5%) had a claim for specific infectious pathogens. The mean age among 18 GBS patients with antecedent CMV infection was 39 years versus 47 years among those without antecedent CMV infection (p = 0.038). CONCLUSIONS: Incidence of GBS using a large national claims database was comparable to that reported in the literature, but cases appeared to be less severe. Half of GBS patients reported prior infectious illness, but only a minority had a specific pathogen identified.
OBJECTIVE: To describe incidence and clinical characteristics of cases of Guillain-Barré syndrome (GBS) in the USA during 2009-2015, and characteristics of GBS cases with antecedent cytomegalovirus (CMV) infection among persons with employer-sponsored insurance. METHODS: We analyzed medical claims from IBM Watson MarketScan® databases. GBSpatients were defined as enrollees with an inpatient claim with GBS as the principal diagnosis code, based on ICD-9 or ICD-10, and ≥ 1 claim for lumbar puncture or EMG/nerve conduction study. We assessed intensive care unit (ICU) hospitalization, intubation, dysautonomia, and death. We also assessed selected infectious illness within 60 days prior to the first GBS-coded inpatient claim. RESULTS: We identified 3486 GBSpatients; annual incidence was 1.0-1.2/100,000 persons during 2009-2015. GBS incidence was higher in males (1.2/100,000) than in females (0.9/100,000) (p = 0.006) and increased with age, from 0.4/100,000 in persons 0-17 years old to 2.1/100,000 in persons ≥ 65 years old (p < 0.001). Half of GBSpatients were hospitalized in the ICU, 8% were intubated, 2% developed dysautonomia, and 1% died. Half had a claim for antecedent illness, but only 125 (3.5%) had a claim for specific infectious pathogens. The mean age among 18 GBSpatients with antecedent CMV infection was 39 years versus 47 years among those without antecedent CMV infection (p = 0.038). CONCLUSIONS: Incidence of GBS using a large national claims database was comparable to that reported in the literature, but cases appeared to be less severe. Half of GBSpatients reported prior infectious illness, but only a minority had a specific pathogen identified.
Entities:
Keywords:
CMV; Cytomegalovirus; GBS-Guillain-Barré syndrome; Healthcare data
Authors: H Inokuchi; H Yasunaga; Y Nakahara; H Horiguchi; N Ogata; J Fujitani; S Matsuda; K Fushimi; N Haga Journal: Eur J Phys Rehabil Med Date: 2014-03-20 Impact factor: 2.874
Authors: Ashley R Styczynski; Juliane M A S Malta; Elisabeth R Krow-Lucal; Jadher Percio; Martha E Nóbrega; Alexander Vargas; Tatiana M Lanzieri; Priscila L Leite; J Erin Staples; Marc X Fischer; Ann M Powers; Gwong-Jen J Chang; P L Burns; Erin M Borland; Jeremy P Ledermann; Eric C Mossel; Lawrence B Schonberger; Ermias B Belay; Jorge L Salinas; Roberto D Badaro; James J Sejvar; Giovanini E Coelho Journal: PLoS Negl Trop Dis Date: 2017-08-30
Authors: Federica Ginanneschi; Fabio Giannini; Francesco Sicurelli; Carla Battisti; Giorgio Capoccitti; Sabina Bartalini; Andrea Mignarri; Nila Volpi; David Cioncoloni; Laura Franci; Nicola De Stefano; Alessandro Rossi Journal: Front Neurol Date: 2022-06-29 Impact factor: 4.086
Authors: Zheng Li; Xingye Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu Journal: Environ Sci Pollut Res Int Date: 2021-03-06 Impact factor: 4.223